Because of the high rate of KRAS mutation in PDAC tumours and pre-neoplastic lesions, a combination of the perfect sampling method and mutation detection technology should allow for a sensitivity approaching 90% for discrimination between PDAC and the healthy state. Here, KRAS is linked to neoplasm.